All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

PHARMACOMPASS

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

Product Type

Companies

MODAG

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

MODAG Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation

Lead Product(s): Anle138b

Therapeutic Area: Neurology Product Name: Anle138b

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: The Michael J. Fox Foundation for Parkinson's Research.

Deal Size: $1.4 million Upfront Cash: Undisclosed

Deal Type: Funding August 05, 2020

Details:

Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in animal models.